Loading…
Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125
The chemokine receptor CXCR3 allows the selective recruitment of innate and adaptive inflammatory immune cells into inflamed tissue. CXCR3 ligands are secreted after exposure to pro-inflammatory cytokines. Upon binding to CXCR3 ligands, CXCR3 expressing T-lymphocytes migrate toward sites of inflamma...
Saved in:
Published in: | Journal of medicinal chemistry 2022-09, Vol.65 (17), p.11533-11549 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963 |
---|---|
cites | cdi_FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963 |
container_end_page | 11549 |
container_issue | 17 |
container_start_page | 11533 |
container_title | Journal of medicinal chemistry |
container_volume | 65 |
creator | Caroff, Eva Meyer, Emmanuel A. Äänismaa, Päivi Froidevaux, Sylvie Keller, Marcel Piali, Luca |
description | The chemokine receptor CXCR3 allows the selective recruitment of innate and adaptive inflammatory immune cells into inflamed tissue. CXCR3 ligands are secreted after exposure to pro-inflammatory cytokines. Upon binding to CXCR3 ligands, CXCR3 expressing T-lymphocytes migrate toward sites of inflammation and can promote tissue damage. Therefore, antagonizing this receptor may provide clinical benefits for patients suffering from autoimmune diseases characterized by high concentrations of CXCR3 ligands. Herein, we report the second part of our CXCR3 discovery program where we explored the benzimidazolo-thiazole core scaffold. The optimization of potency and the mitigation of an hERG liability are described. Further pharmacokinetic considerations led to the identification of the potent CXCR3 antagonist ACT-672125 (29). The compound showed good physicochemical properties and safety profile. In a proof-of-mechanism model of lung inflammation, ACT-672125 inhibited the recruitment of CXCR3 expressing T cells into the inflamed lung in a dose-dependent manner. |
doi_str_mv | 10.1021/acs.jmedchem.2c00676 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2702484286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2702484286</sourcerecordid><originalsourceid>FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCVWFr-AQcfOTSLPc4ntyUtBakSFSwSt2jqTDauEnuxnaLt3-ofJGGXK6d50rz35uMx9laKtRQg36MO64eRWt3TuAYtRF7kL9hKZiCStBTpS7YSAiCBHNQr9jqEByGEkqBW7PmKgtnZS_79YGM_43DJ0bb8rkc_onaD2xmNA79-xGHCaJzlruMfyT6Z0bT4NBOS2JsFUOAY-J2LZCOvf9bfFN_YiDtnTYiB_zax59uePO5pikafmGY2N5ZvpujMOE6W-JUJhIHChwVp90j-sMzc1NskL0BCdsHOOhwCvTnVc_bj0_W2_pzcfr35Um9uE1SQxQSx0KCwSkvsslJnhRSkMK-gnd8gVH5fAkgqqK26UmSg1L3KU0BVqaIrsipX5-zd0Xfv3a-JQmzGeSEaBrTkptBAISAtUygXanqkau9C8NQ1e29G9IdGimbJqJkzav5l1JwymmXiKPvbdZO38z3_l_wB1M-aDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2702484286</pqid></control><display><type>article</type><title>Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Caroff, Eva ; Meyer, Emmanuel A. ; Äänismaa, Päivi ; Froidevaux, Sylvie ; Keller, Marcel ; Piali, Luca</creator><creatorcontrib>Caroff, Eva ; Meyer, Emmanuel A. ; Äänismaa, Päivi ; Froidevaux, Sylvie ; Keller, Marcel ; Piali, Luca</creatorcontrib><description>The chemokine receptor CXCR3 allows the selective recruitment of innate and adaptive inflammatory immune cells into inflamed tissue. CXCR3 ligands are secreted after exposure to pro-inflammatory cytokines. Upon binding to CXCR3 ligands, CXCR3 expressing T-lymphocytes migrate toward sites of inflammation and can promote tissue damage. Therefore, antagonizing this receptor may provide clinical benefits for patients suffering from autoimmune diseases characterized by high concentrations of CXCR3 ligands. Herein, we report the second part of our CXCR3 discovery program where we explored the benzimidazolo-thiazole core scaffold. The optimization of potency and the mitigation of an hERG liability are described. Further pharmacokinetic considerations led to the identification of the potent CXCR3 antagonist ACT-672125 (29). The compound showed good physicochemical properties and safety profile. In a proof-of-mechanism model of lung inflammation, ACT-672125 inhibited the recruitment of CXCR3 expressing T cells into the inflamed lung in a dose-dependent manner.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.2c00676</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2022-09, Vol.65 (17), p.11533-11549</ispartof><rights>2022 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963</citedby><cites>FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963</cites><orcidid>0000-0003-0851-0550</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Caroff, Eva</creatorcontrib><creatorcontrib>Meyer, Emmanuel A.</creatorcontrib><creatorcontrib>Äänismaa, Päivi</creatorcontrib><creatorcontrib>Froidevaux, Sylvie</creatorcontrib><creatorcontrib>Keller, Marcel</creatorcontrib><creatorcontrib>Piali, Luca</creatorcontrib><title>Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The chemokine receptor CXCR3 allows the selective recruitment of innate and adaptive inflammatory immune cells into inflamed tissue. CXCR3 ligands are secreted after exposure to pro-inflammatory cytokines. Upon binding to CXCR3 ligands, CXCR3 expressing T-lymphocytes migrate toward sites of inflammation and can promote tissue damage. Therefore, antagonizing this receptor may provide clinical benefits for patients suffering from autoimmune diseases characterized by high concentrations of CXCR3 ligands. Herein, we report the second part of our CXCR3 discovery program where we explored the benzimidazolo-thiazole core scaffold. The optimization of potency and the mitigation of an hERG liability are described. Further pharmacokinetic considerations led to the identification of the potent CXCR3 antagonist ACT-672125 (29). The compound showed good physicochemical properties and safety profile. In a proof-of-mechanism model of lung inflammation, ACT-672125 inhibited the recruitment of CXCR3 expressing T cells into the inflamed lung in a dose-dependent manner.</description><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v1DAQtRCVWFr-AQcfOTSLPc4ntyUtBakSFSwSt2jqTDauEnuxnaLt3-ofJGGXK6d50rz35uMx9laKtRQg36MO64eRWt3TuAYtRF7kL9hKZiCStBTpS7YSAiCBHNQr9jqEByGEkqBW7PmKgtnZS_79YGM_43DJ0bb8rkc_onaD2xmNA79-xGHCaJzlruMfyT6Z0bT4NBOS2JsFUOAY-J2LZCOvf9bfFN_YiDtnTYiB_zax59uePO5pikafmGY2N5ZvpujMOE6W-JUJhIHChwVp90j-sMzc1NskL0BCdsHOOhwCvTnVc_bj0_W2_pzcfr35Um9uE1SQxQSx0KCwSkvsslJnhRSkMK-gnd8gVH5fAkgqqK26UmSg1L3KU0BVqaIrsipX5-zd0Xfv3a-JQmzGeSEaBrTkptBAISAtUygXanqkau9C8NQ1e29G9IdGimbJqJkzav5l1JwymmXiKPvbdZO38z3_l_wB1M-aDQ</recordid><startdate>20220908</startdate><enddate>20220908</enddate><creator>Caroff, Eva</creator><creator>Meyer, Emmanuel A.</creator><creator>Äänismaa, Päivi</creator><creator>Froidevaux, Sylvie</creator><creator>Keller, Marcel</creator><creator>Piali, Luca</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0851-0550</orcidid></search><sort><creationdate>20220908</creationdate><title>Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125</title><author>Caroff, Eva ; Meyer, Emmanuel A. ; Äänismaa, Päivi ; Froidevaux, Sylvie ; Keller, Marcel ; Piali, Luca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caroff, Eva</creatorcontrib><creatorcontrib>Meyer, Emmanuel A.</creatorcontrib><creatorcontrib>Äänismaa, Päivi</creatorcontrib><creatorcontrib>Froidevaux, Sylvie</creatorcontrib><creatorcontrib>Keller, Marcel</creatorcontrib><creatorcontrib>Piali, Luca</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caroff, Eva</au><au>Meyer, Emmanuel A.</au><au>Äänismaa, Päivi</au><au>Froidevaux, Sylvie</au><au>Keller, Marcel</au><au>Piali, Luca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2022-09-08</date><risdate>2022</risdate><volume>65</volume><issue>17</issue><spage>11533</spage><epage>11549</epage><pages>11533-11549</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>The chemokine receptor CXCR3 allows the selective recruitment of innate and adaptive inflammatory immune cells into inflamed tissue. CXCR3 ligands are secreted after exposure to pro-inflammatory cytokines. Upon binding to CXCR3 ligands, CXCR3 expressing T-lymphocytes migrate toward sites of inflammation and can promote tissue damage. Therefore, antagonizing this receptor may provide clinical benefits for patients suffering from autoimmune diseases characterized by high concentrations of CXCR3 ligands. Herein, we report the second part of our CXCR3 discovery program where we explored the benzimidazolo-thiazole core scaffold. The optimization of potency and the mitigation of an hERG liability are described. Further pharmacokinetic considerations led to the identification of the potent CXCR3 antagonist ACT-672125 (29). The compound showed good physicochemical properties and safety profile. In a proof-of-mechanism model of lung inflammation, ACT-672125 inhibited the recruitment of CXCR3 expressing T cells into the inflamed lung in a dose-dependent manner.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.jmedchem.2c00676</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0851-0550</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2022-09, Vol.65 (17), p.11533-11549 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_2702484286 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
title | Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20Synthesis,%20and%20Pharmacological%20Evaluation%20of%20Benzimidazolo-thiazoles%20as%20Potent%20CXCR3%20Antagonists%20with%20Therapeutic%20Potential%20in%20Autoimmune%20Diseases:%20Discovery%20of%20ACT-672125&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Caroff,%20Eva&rft.date=2022-09-08&rft.volume=65&rft.issue=17&rft.spage=11533&rft.epage=11549&rft.pages=11533-11549&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.2c00676&rft_dat=%3Cproquest_cross%3E2702484286%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a325t-aa7c23a948af58c5710e3a692d623036b8221e7ed9f805233b3642a3937f75963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2702484286&rft_id=info:pmid/&rfr_iscdi=true |